A plan to let Charlotte-based Atrium Health take over Raleigh-based WakeMed has generated skepticism and opposition from state and local officials on both sides of the aisle. State lawmakers, the ...

Charlotte, N.C.-based Atrium Health and Raleigh, N.C.-based WakeMed Health & Hospitals announced on May 1 plans to combine into a single health system, which the organizations said involves a $2 ...

The Wake County Board of Commissioners plans to vote Monday to alter WakeMed's articles of incorporation and a land deal between the county and hospital system to pave the way for a merger with ...

Atrium Health plans to take control of WakeMed in a deal that could bring at least $2 billion in new investment to Wake County, documents filed with Wake County indicate. It also lets Atrium grow its ...

WAKE COUNTY, N.C. (WTVD) -- WakeMed could soon be part of Atrium Health in Charlotte. The announcement was made on Friday afternoon in a news release. WakeMed says pending all applicable approvals, ...

Add Yahoo as a preferred source to see more of our stories on Google. Stopping to smell the roses doesn't just help you slow down and appreciate life; studies show it can also improve your mental and ...

Ford Foundation's Atrium Garden offers secret oasis in Midtown Manhattan Tue, April 28, 2026 at 6:00 PM PDT 0 Ford Foundation's Atrium Garden offers secret oasis in Midtown Manhattan ...

Hidden garden inside New York atrium offers urban oasis, study shows benefits of nature To stream CBS19 on your phone, you need the CBS19 app.

Kathleen Gallagher is chief executive of Atrium, which is developing siRNA therapies for genetic cardiomyopathies. As Novartis completed its $12 billion takeover of Avidity, a new cardiology-focused ...

When Novartis agreed to buy RNA therapies developer Avidity Biosciences last fall, the companies said the plan was to spin out Avidity’s cardiology assets into a separate, publicly traded company.

A new biotech has taken flight as a result of Novartis’ red-hot $12 billion acquisition of muscular dystrophy specialist Avidity Biosciences. A spinout planned since that deal’s October announcement ...